In disease- or cancer-induced muscle atrophy models, CBP/p300 is typically phosphorylated, and phosphorylated CBP/p300 enhances its acetyltransferase activity, leading to morphological and molecular changes associated with atrophy [150,151,152,153]. Here, CREBBP is linked to muscle atrophy.